Immune Checkpoint Inhibitor Outcomes for Patients With Non–Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications Median time to relapse was 7.4 ...

Standardization of 18F-FDG–PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma We analyzed patients with relapse after ES-HL treated ...

Approximately 20% of patients with clinical stage I seminoma relapse. Tumor size and rete testis invasion have been identified as risk factors for relapse. However, the level of evidence supporting ...

With fenebrutinib, the company aims to launch a new oral treatment for multiple sclerosis that offers both greater ...

Investigators sought to determine whether adjuvant pembrolizumab is associated with the risk of developing subsequent cutaneous malignant neoplasms in patients with high-risk stage II melanoma.

More than half of patients with BRAF-mutated advanced melanoma taking Tafinlar+ Mekinist were alive and free of a relapse at 5- years 1 Study conclusions are drawn from the largest dataset and longest ...

A second clinical trial testing fenebrutinib for MS has met its main goal, once again beating approved Aubagio in reducing ...

International guidelines advocate for active surveillance as the preferred treatment strategy for patients with stage 1 testicular cancer after orchidectomy although a personalized discussion is ...